Hyperium Neoplasm Malignant Side Effect Reports
The following Hyperium Neoplasm Malignant side effect reports were submitted by healthcare professionals and consumers.
This information will help you understand how side effects, such as Neoplasm Malignant, can occur, and what you can do about them.
A side effect could appear soon after you start Hyperium or it might take time to develop.
|Muscular Weakness, Metastases To Bone, Adenocarcinoma, Chronic Myeloid Leukaemia, Metastases To Liver, Neoplasm Malignant, Polyneuropathy, Metastases To Spleen, Myalgia|
This Neoplasm Malignant side effect was reported by a physician from FRANCE. A patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Hyperium (dosage: NA), which was started on Jan 14, 2011. Concurrently used drugs:
Hyperium Neoplasm Malignant Causes and Reviews
Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.
NIH: National Cancer Institute
Hyperium Neoplasm Malignant ReviewsNo reviews submitted yet, check in later.